E-DRUG: Independent Drug and Healthcare Newsletter for November 2018
----------------------------------------------------------------------------------------
November 2018
Independent Drug & Healthcare Newsletter
from the non-profit journal Prescrire International
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW Drug-induced gynaecomastia
Drug-related proliferation of male breast tissue generally subsides after discontinuation of the substance that caused it. This must be weighed against the potential disadvantages of stopping treatment or substituting another drug.
Read more
--------------------------------------------------------------------------------
FREE DOWNLOAD In the November issue of Prescrire International: Ending pharmaceutical sales representatives' access to hospitals and students.
In-person promotion of drugs to healthcare professionals by pharmaceutical sales representatives, known as pharmaceutical detailing, has been shown to influence doctors' prescribing behaviour. A US study looked at ways to limit this influence.
Read more
--------------------------------------------------------------------------------
SUBSCRIBE ONLINE Subscribe today for instant access to top-quality content from Prescrire International
Enjoy instant access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries).
Subscribe now
--------------------------------------------------------------------------------
Alcohol dependence: the risks of high-dose baclofen
With high-dose baclofen, there is an increased risk of epilepsy, infection, myocardial infarction or suicidal thoughts.
Read more
english.prescrire.org/en/81/168/55370/0/NewsDetails.aspx
--------------------------------------------------------------------------------
Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance
Reports of sometimes serious adverse effects tilt the harm-benefit balance of denosumab in the treatment of osteoporosis.
Read more
--------------------------------------------------------------------------------
Venetoclax (Venclyxto°): another drug made available on the market too soon
Ventoclax inhibits a protein often present in abnormal lymphocytes in cases of chronic lymphocytic leukaemia. But does venetoclax extend the patient's life span? We don't know because we don't have a comparative trial.
Read more
--------------------------------------------------------------------------------
Health technology assessment: the European Parliament's position improves substantially upon the Commission proposal
The European Parliament (EP) has adopted by a large majority its position on the proposed Regulation on health technology assessment (HTA). For Prescrire, the EP's position improves the Commission proposal to a great extent by outlining evaluation needs and improving transparency and independence.
Read more
--------------------------------------------------------------------------------
COMING SOON Enjoy these features, and more, in our upcoming issues
Nasal naloxone in opioid overdose * Valproic acid and pregnancy * Fluoroquinolones and ACE inhibitors * Hormonal contraception and suicide * Rivaroxaban and unstable angina * Omalizumab and severe asthma * Prices for hepatitis C drugs * Healthcare-related errors...
Subscribe now
Prescrire International <international@prescrire.org>